Combining nCRT with PD-L1 inhibitors (e.g., envafolimab) may synergistically enhance CD8+ T cell infiltration and activity: nCRT increases antigen presentation and PD-L1 expression on tumor cells, while PD-L1 blockade reverses T cell exhaustion (20). Here, CD8A is linked to neoplasm.